Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
WATERTOWN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Jean Franchi as the company’s Chief Financial Officer. Ms. Franchi will be responsible for finance, investor relations, and other functions and will lead the company’s capital formation and financial strategy. She succeeds Joanne Bryce, who will transition to a consulting role with the company.
Related news for (IRON)
- Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
- Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
- Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
- Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)
- Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update